6-K 1 form6k.htm

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

15 June 22, 2006

Cambridge Antibody Technology Group PLC (Translation of Registrant’'s Name Into English)

Milstein Building, Granta Park, Cambridge, CB1 6GH, England
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or ~~will~~ will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ~~____X____~~ X Form 40-F ________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):__

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):__

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of ~~193~~ 1934.

Yes _________ No ~~____X_____~~ X

If “"Yes”" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82-~~___________~~_____________

EXHIBIT INDEX

This filing contains the following exhibits.


This filing contains the following exhibits.

EXHIBIT	DESCRIPTION

99.1	Press release regarding appointment of Director and Chief Executive

EXHIBIT DESCRIPTION

99.1 Rule 2.10 Announcement released on 15 June, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 15 June, 2006 Cambridge Antibody Technology Group PLC


Date: 22 June 2006	Cambridge Antibody Technology Group PLC

	By:	/s/ Rowena Gardner
		Name: Rowena Gardner
		Title: Director of Corporate Communications

By: /s/ John Aston Name: John Aston Title: Chief Financial Officer

EXHIBIT 99.1

                                                           ANNOUNCEMENT
FOR IMMEDIATE RELEASE
15 June 2006
                                            CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ("CAT")
                                                        RULE 2.10 ANNOUNCEMENT

CAT announces, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers, that subsequent to an issue of 393 ordinary
shares under the CAT Company Share Option Plan (OCSOPO), its issued share capital as at 15 June 2006 comprises 53,206,786 ordinary
shares of 10p each (including those represented by American Depositary Shares) ("CAT Shares").

The ISIN reference number for the CAT Shares is GB0001662252 and for the American Depositary Shares of CAT is US1321481079.

Enquiries:

Justin Hoskins (Company Secretary), CAT

Tel: +44 (0) 1223 741 741

END

Filing Compare · CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC